The Seres Therapeutics Inc. (NASDAQ:MCRB) Receives $30.00 Average PT from Brokerages

The Seres Therapeutics Inc. (NASDAQ:MCRB) Receives $30.00 Average PT from Brokerages

Shares of Seres Therapeutics Inc. (NASDAQ:MCRB) have received an average recommendation of “Buy” from the nine research firms that are presently covering the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $30.00.

Several brokerages have recently commented on MCRB. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Tuesday, July 19th. Leerink Swann reiterated a “buy” rating and set a $12.00 price objective on shares of Seres Therapeutics in a research report on Thursday, August 11th. HC Wainwright assumed coverage on Seres Therapeutics in a research report on Friday, July 29th. They set a “buy” rating and a $50.00 price target on the stock. Canaccord Genuity restated a “buy” rating and set a $20.00 price target on shares of Seres Therapeutics in a research report on Monday, August 1st. Finally, FBR & Co restated a “buy” rating on shares of Seres Therapeutics in a research report on Friday, July 8th.

In other Seres Therapeutics news, insider John G. Aunins sold 9,390 shares of the stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $10.87, for a total value of $102,069.30. Following the completion of the sale, the insider now owns 192,125 shares in the company, valued at approximately $2,088,398.75. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Michele Trucksis sold 38,064 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $35.14, for a total value of $1,337,568.96. Following the completion of the sale, the insider now owns 38,064 shares of the company’s stock, valued at approximately $1,337,568.96. The disclosure for this sale can be found here. 41.90% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the company. Birchview Capital LP acquired a new stake in Seres Therapeutics during the second quarter valued at $145,000. Pacad Investment Ltd. acquired a new stake in Seres Therapeutics during the second quarter valued at $198,000. First Mercantile Trust Co. acquired a new stake in Seres Therapeutics during the second quarter valued at $229,000. GSA Capital Partners LLP acquired a new stake in Seres Therapeutics during the second quarter valued at $273,000. Finally, American International Group Inc. boosted its stake in Seres Therapeutics by 106.4% in the second quarter. American International Group Inc. now owns 10,262 shares of the company’s stock valued at $298,000 after buying an additional 5,290 shares during the period. Institutional investors and hedge funds own 78.28% of the company’s stock.

Shares of Seres Therapeutics (NASDAQ:MCRB) opened at 11.525 on Monday. Seres Therapeutics has a 12-month low of $8.05 and a 12-month high of $44.51. The company’s market cap is $464.16 million. The stock’s 50 day moving average price is $11.79 and its 200 day moving average price is $23.11.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.24. The firm earned $3 million during the quarter, compared to analysts’ expectations of $4.20 million. The company’s revenue was up NaN% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.45) EPS. On average, analysts forecast that Seres Therapeutics will post ($2.33) EPS for the current year.

Related posts

Leave a Comment